依那普利对冠脉介入患者肾功能的影响

目的 观察血管紧张素转换酶抑制剂依那普利对行冠状动脉介入治疗患者肾功能的影响.方法 146例行单纯冠脉造影术或经皮冠状动脉介入治疗患者随机分为依那普利组(72例)和对照组(74例),依那普利组患者至少术前2天至术后2天给予马来酸依那普片5～ 10mg 2次/d.比较术前及术后48 h内血清肌酐(Scr)、尿素氮(BUN)、胱抑素C(Cys C)及肾小球滤过率估测值(eGFR).结果 对照组术后Scr由基线( 69.79±16.77)升至(71.80±15.98)μmol/L(P＜0.05),eGFR由基线(112.19±33.08)降至(106.64±24.65)mL/min (P ＜0.01),Cys C由基线(0.57±0.11)升至(0.62±0.22 )mg/L(P ＜0.05).依那普利组手术前后Scr、eGFR、Cys C差异无显著性(P＞0.05).结论 依那普利可能有预防对比剂肾病的作用.

Efficacy of enalapri on renal function in patients undergoing percutaneous coronary intervention

【Objective】 To investigate the efficacy of angiotensin-converting enzyme inhibitor enalapri maleate tablets on renal function in patients undergoing percutanous coronary intervention.【Methods】 146 consecutive patients undergoing diagnostic coronary angiography(CAG) or percutaneous coronary intervention(PCI) were assigned to enalapri group(n =72) and control group(n =74) randomly.In the enalapri group,the patients receive enalapri maleate tablets 5～10 mg twice daily more than 2 days before and after CAG or PCI.We compared serum creatinine(Scr),blood urea nitrogen(BUN),cystatin C(Cys C) levels,and estimated glomerular filatration rate(eGFR) at baseline and 48 h after CAG or PCI.【Results】 In the control group Scr increased from(69.79±16.77) to(71.80±15.98) μmol/L(P <0.05),eGFR decreased from(112.19±33.08) to(106.64±24.65) mL/min(P <0.01),and Cys C increased from(0.57±0.11) to(0.62±0.22) mg/L(P <0.05).In the enalapri group,Scr,eGFR and Cys C were unchanged.【Conclusions】 These results suggested that enalapri maleate tablets are effective in preventing contrast-induced nephropathy.